Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! By
Efficacy of Direct Acting Antivirals (Daa) Therapy in Patients With Recurrent Hepatitis C After Liver and Kidney Transplantation: A Cross-Sectional Study Publisher



M Kashani MEHDI ; M Karimi MEHDI ; A Sharifi Rayeni ALIREZA ; Ma Azizi Nadian Mohammad ALI ; M Mortezazadeh MASOUD ; A Parsaei AMIRHOSSEIN ; N Abolghasemi NOOSHIN ; N Shirsalimi NIYOUSHA ; A Mofidi ABBAS ; St Seyyed Mahmoudi Seyyed TAHER
Authors

Source: Frontiers in Medicine Published:2024


Abstract

Background and objectives: Direct-acting antiviral (DAA) agents are now widely used to treat patients with hepatitis C infection (HCV) and effectively increase their sustained virologic response (SVR). However, the literature seems to lack or deficient evidence of DAA efficacy in more complicated patients, especially those with HCV reinfection after liver transplantation (LT) or liver-kidney (hepatorenal) transplantation (LKT). This study aimed to retrospectively evaluate the effectiveness of two different DAA regimens in LT and LKT patients with HCV reinfection. Methods: This cross-sectional study was conducted at three hospitals in Tehran, Iran, from 2014 to 2020, enrolling 53 patients with recurrent HCV infection after LT (n = 35) or LKT (n = 18). Patients were treated for 12 weeks with one of two DAA regimens: 37 patients (70%) received Daclatasvir and Sofosbuvir (SOF + DCV), while 16 patients (30%) received Sofosbuvir and Ledipasvir (SOF + LDV). Ribavirin (RBV) was added as an adjunct antiviral in 28 patients (52.8%). To assess the SVR, all patients were followed for 12 weeks after treatment. Results: Both DAA regimens were well-tolerated and effective, with 94.6% (35 of 37) achieving SVR-12 in the SOF + DCV group and 93.8% (15 of 16) in the SOF + LDV group. Additionally, SVR-12 rates were promising across treatment durations, with 93.9% (31 of 33) in the 12-week group and 95% (19 of 20) in the 24-week group achieving undetectable HCV RNA. No significant difference in SVR was observed between the two regimens (p = 0.439). Conclusion: The DAA-based therapeutic regimen was well tolerated and showed significant effectiveness in achieving the virologic response in patients with HCV reinfection after LT or LKT. © 2024 Elsevier B.V., All rights reserved.
Related Docs
View other Related Docs
1. Efficacy of Locally Manufactured Sofosbuvir and Daclatasvir (Sovodak) in Combination With Ribavirin in Treating Patients With Chronic Hepatitis C and Cirrhosis in Iran - Preliminary Report, Govaresh (2016)
2. An Overview of the Current Hepatitis B Treatment Strategies After Liver Transplantation, Middle East Journal of Digestive Diseases (2021)
3. Safety and Efficacy of Adding Ribavirin to Interferon or Peginterferon in Treatment of Hepatitis C Infection in Patients With Thalassemia: A Systematic Review on Randomized Controlled Trials, Hepatitis Monthly (2016)
Experts (# of related papers)
View all Related Experts
Reza Malekzadeh (8)
Hossein Poustchi (8)
Other Related Docs
4. Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline, Hepatitis Monthly (2016)
5. Sofosbuvir/Daclatasvir Regimens for the Treatment of Covid-19: An Individual Patient Data Meta-Analysis, Journal of Antimicrobial Chemotherapy (2021)
6. Historical Epidemiology of Hepatitis C Virus (Hcv) in Select Countries - Volume 3, Journal of Viral Hepatitis (2015)
7. Remdesivir: Treatment of Covid-19 in Special Populations, Naunyn-Schmiedeberg's Archives of Pharmacology (2024)
8. An Intervention to Increase Hepatitis C Virus Diagnosis and Treatment Uptake Among People in Custody in Iran, International Journal of Drug Policy (2021)
9. The Combination of Sofosbuvir and Daclatasvir Is Effective and Safe in Treating Patients With Hepatitis C and Severe Renal Impairment, Journal of Gastroenterology and Hepatology (Australia) (2020)
10. Prevalence of Hepatitis C Infection in Iranian Hemodialysis Patients: An Updated Systematic Review and Meta-Analysis, Journal of Research in Medical Sciences (2017)
11. Continuum of Hepatitis C Care Cascade in Prison and Following Release in the Direct-Acting Antivirals Era, Harm Reduction Journal (2020)
12. The Predictive Factors for Favorable Outcomes of Peginterferon and Ribavirin Combination Therapy in Hcv-Infected Patients, Acta Medica Iranica (2020)
13. Sofosbuvir and Daclatasvir Compared With Standard of Care in the Treatment of Patients Admitted to Hospital With Moderate or Severe Coronavirus Infection (Covid-19): A Randomized Controlled Trial, Journal of Antimicrobial Chemotherapy (2020)
14. Update on the Prevalence of Hepatitis C Virus Infection Among Iranian General Population: A Systematic Review and Meta-Analysis, Hepatitis Monthly (2017)
15. The Impact of Sofosbuvir/Daclatasvir or Ribavirin in Patients With Severe Covid-19, Journal of Antimicrobial Chemotherapy (2020)
16. Sd1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-Cost, Fixed-Dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase Iii Clinical Trial, Clinical Infectious Diseases (2020)
17. Characterization of Occult Hepatitis B Infection Among Iranian Liver Transplant Recipients, Journal of Clinical Laboratory Analysis (2022)
18. The Prevalence of Hepatitis C Virus Core Amino Acid 70 Substitution and Genotypes of Polymorphisms Near the Ifnl3 Gene in Iranian Patients With Chronic Hepatitis C, Hepatitis Monthly (2016)
19. An Updated Systematic Review and Metaanalysis on Efficacy of Sofosbuvir in Treating Hepatitis C-Infected Patients With Advanced Chronic Kidney Disease, PLoS ONE (2021)
20. Hbig Remains Significant in the Era of New Potent Nucleoside Analogues for Prophylaxis Against Hepatitis B Recurrence After Liver Transplantation, International Reviews of Immunology (2016)